Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 6/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ADK | P55263 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18588900 | 0.91 | KMT2A (0.37) | KMT2AMEN1NPC1RAB9ACHEK1 | |
| SCHEMBL18588884 | 0.83 | KMT2A (0.39) | KMT2AMEN1NPC1RAB9ACHEK1 | |
| SCHEMBL18581942 | 0.79 | ADORA1 (0.41) | — | |
| SCHEMBL18588912 | 0.77 | DGAT1 (0.34) | — | |
| SCHEMBL18582026 | 0.77 | DGAT1 (0.34) | — | |
| SCHEMBL20363396 | 0.75 | ATG7 (0.33) | — | |
| SCHEMBL18582019 | 0.75 | ATG7 (0.33) | — | |
| SCHEMBL18588892 | 0.75 | ATG7 (0.33) | — | |
| SCHEMBL18603131 | 0.75 | ATG7 (0.33) | — | |
| SCHEMBL20363406 | 0.75 | ATG7 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017512-B2 | Compounds and compositions useful for treating disorders related to NTRK | BLUEPRINT MEDICINES CORPORATION (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170066773-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066773-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | NTRK2, NTRK3, NTRK1 | KMT2A 3044/4885MEN1 3209/4885NPC1 211/4885 |
| US-10017512-B2 | Compounds and compositions useful for treating disorders related to NTRK | NTRK3, NTRK2, NTRK1 | KMT2A 2823/4885MEN1 2489/4885NPC1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.